Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 14:20 save search
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
Published: 2023-07-18 (Crawled : 14:20) - biospace.com/
BSTG 4 | $4.03 67.25% 4.5K
|
Manufacturing
|
| O: 3.36%
H: 11.0%
C: 0.0%
disease trial
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
Published: 2023-07-17 (Crawled : 14:20) - biospace.com/
DHR | $250.41 -1.07% -0.72% 3.3M
|
Health Technology
|
| O: -0.16%
H: 0.12%
C: -1.0%
disease test alzheimer's
PTC, chasing BioMarin, posts phase 3 rare disease win but fails to … – FierceBiotech
Published: 2023-05-18 (Crawled : 14:20) - spacfeed.com
SOFI D | $7.6 0.26% 0.26% 39M
|
Finance and Insurance
|
| O: 0.4%
H: 3.11%
C: 1.81%
rare disease
FDA Approves Fabry Disease Treatment from Chiesi, Protalix
Published: 2023-05-10 (Crawled : 14:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: 0.0%
fda disease treatment
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-03-21 (Crawled : 14:20) - globenewswire.com
VRDN | $13.04 -8.49% -9.28% 770K
|
Health Care and Social Assistan...
|
| O: 0.75%
H: 6.59%
C: 1.34%
vrdn-002 disease antibody treatment thyroid eye trial therapeutics
Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease
Published: 2022-11-10 (Crawled : 14:20) - globenewswire.com
GENE | News 0 d | $2.16 -9.62% -10.65% 28K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.45%
disease risk
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - globenewswire.com
GRTX | $0.1821 -6.13% -6.53% 810K
|
Health Technology
|
| O: 0.36%
H: 0.72%
C: 0.18%
disease kidney meeting trial
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
Published: 2023-03-29 (Crawled : 14:20) - biospace.com/
WVE | $5.01 -1.38% -1.4% 430K
|
Health Technology
|
| O: 0.5%
H: 11.66%
C: 7.94%
rare disease life genomic sciences
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2023-02-08 (Crawled : 14:20) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.0%
H: 5.42%
C: -1.24%
treatment sciences disease alzheimer’s update
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Published: 2023-01-24 (Crawled : 14:20) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: -6.97%
H: 1.97%
C: -13.16%
sciences disease alzheimer’s positive results study phase 2
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
Published: 2023-01-12 (Crawled : 14:20) - biospace.com/
CDXC | $3.4 0.0% 180K
|
Process Industries
|
| O: 0.5%
H: 1.49%
C: 1.49%
disease neurodegenerative
Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
Published: 2022-12-15 (Crawled : 14:20) - biospace.com/
SEEL | $0.2971 -9.17% -10.1% 600K
|
Health Technology
|
| O: 3.1%
H: 0.0%
C: -18.05%
sls-004 disease parkinson's therapeutics therapy study
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
Published: 2022-12-06 (Crawled : 14:20) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.0%
H: 4.56%
C: -0.36%
sciences disease alzheimer’s study
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project
Published: 2022-12-05 (Crawled : 14:20) - biospace.com/
CPHI | $0.315 -0.76% -0.95% 1.1M
|
Health Technology
|
| O: 15.15%
H: 89.15%
C: 25.38%
acquisition pharma device disease eye china
BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting
Published: 2022-11-15 (Crawled : 14:20) - biospace.com/
BIVI | $0.5025 2.18% 2.13% 850K
|
Health Technology
|
| O: 3.73%
H: 0.0%
C: -6.05%
ne3107 treatment disease alzheimer's meeting biomarker trial imaging
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
Published: 2022-11-15 (Crawled : 14:20) - prnewswire.com
OCEL | $2.75 -98.44% 3.4K
|
Professional, Scientific, and T...
|
| O: 20.68%
H: 22.74%
C: 12.15%
BRTX | $1.26 -5.97% -6.35% 75K
|
Professional, Scientific, and T...
|
| O: 0.66%
H: 4.59%
C: -3.61%
VCEL | $46.09 -0.71% -0.72% 200K
|
Health Technology
|
| O: 2.6%
H: 1.14%
C: -1.73%
MDXG | $6.44 -1.08% -1.09% 650K
|
Health Technology
|
| O: 3.69%
H: 3.86%
C: 2.37%
disease expected market
Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-09-12 (Crawled : 14:20) - biospace.com/
RGLS | $2.23 -1.33% -1.35% 92K
|
Health Technology
|
| O: 11.31%
H: 28.34%
C: 3.74%
rgls8429 treatment disease topline kidney trial therapeutics positive
American Diabetes Association Focuses on Prevention of Kidney Disease through Collaboration with DaVita
Published: 2022-07-25 (Crawled : 14:20) - prnewswire.com
DVA | News | $132.74 -0.87% 0.0% 470K
|
Health Services
|
| O: 0.09%
H: 1.28%
C: -1.48%
disease collaboration kidney diabetes
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
Published: 2022-07-14 (Crawled : 14:20) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.65%
H: 0.15%
C: -1.05%
disease brazil program
SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update
Published: 2022-07-14 (Crawled : 14:20) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: -4.19%
disease update international study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.